Although an increase in blasts exists in most AML cases with mutated NPM1, if the blast count is < 10%, the diagnosis is changed to “AML with NPM1” in WHO2022 and “NPM1-mutated myelodysplastic syndrome (MDS)” in ICC. Here, NPM1 is linked to intrahepatic cholangiocarcinoma.